Abstract
Pityriasis Rubra Pilaris (PRP) is a rare inflammatory dermatosis, clinically presenting as a keratinization disorder, with follicular and palmoplantar hyperkeratosis, in addition to orange-red scaly plaques, accompanied by characteristic islands of healthy skin. Sometimes, conventional treatment proves to be ineffective, and this work aims to present a case of a patient with failed first and second lines treatment options, responding well to adalimumab. Despite of all options available, more qualified and specific studies are needed to establish a standardized treatment based on evidence of a high scientific level, thus raising the degree of efficacy and therapeutic safety in PRP.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
